Treasurer of the State of North Carolina Buys 47,720 Shares of Johnson & Johnson (NYSE:JNJ)

Treasurer of the State of North Carolina lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,155,604 shares of the company’s stock after purchasing an additional 47,720 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Treasurer of the State of North Carolina’s portfolio, making the stock its 22nd largest position. Treasurer of the State of North Carolina’s holdings in Johnson & Johnson were worth $167,123,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after acquiring an additional 329,473 shares in the last quarter. Financial Avengers Inc. lifted its holdings in Johnson & Johnson by 3.0% in the third quarter. Financial Avengers Inc. now owns 43,472 shares of the company’s stock valued at $7,045,000 after acquiring an additional 1,276 shares during the period. Neo Ivy Capital Management bought a new position in shares of Johnson & Johnson in the third quarter worth about $242,000. TD Private Client Wealth LLC grew its holdings in Johnson & Johnson by 41.3% during the 3rd quarter. TD Private Client Wealth LLC now owns 33,076 shares of the company’s stock valued at $5,360,000 after buying an additional 9,671 shares in the last quarter. Finally, Soltis Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 3.7% in the 3rd quarter. Soltis Investment Advisors LLC now owns 37,577 shares of the company’s stock worth $6,090,000 after purchasing an additional 1,357 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Finally, Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $172.33.

Johnson & Johnson Trading Down 0.7 %

Johnson & Johnson stock opened at $149.02 on Thursday. The company has a 50 day moving average price of $159.50 and a 200 day moving average price of $155.37. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $359.10 billion, a price-to-earnings ratio of 22.41, a P/E/G ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.